Influence of Diabetes Mellitus on Early and Late Outcome After Percutaneous Transluminal Coronary Angioplasty

Stein, Bernardo; Weintraub, William S.; Gebhart, Suzanne; Cohen-Bernstein, Caryn L.; Grosswald, Ralph; Liberman, Henry; Douglas, John S.; Morris, Douglas C.; King, Spencer B.

doi:10.1161/01.cir.91.4.979

Cited by 465 publications

(219 citation statements)

References 29 publications

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…[19][20][21] Furthermore, diabetes is associated with coronary artery stenosis and sudden cardiac death in patients hospitalized with heart failure. 22,23) As past research has shown, inflammation is a common factor in all stages of diabetes mellitus and heart failure.…”

Section: Discussionmentioning

confidence: 99%

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients

Zhang

et al. 2017

Int. Heart J.

View full text Add to dashboard Cite

SummaryInflammation plays an important role in heart failure and diabetes mellitus. Traditional serum markers have limited predictive value in heart failure and diabetes. TNFR1 and TNFR2 (TNFR1/2) have been proven to be strongly associated with heart failure and diabetes complications. This study aimed to assess the association of sTNFR1 and sTNFR2 levels and incidental HF risk in diabetes patients.We detected the mRNA, protein, and serum expression of TNFR1/2, their downstream signaling pathway protein NF-kB, and JNK expression and some traditional serum inflammatory markers in a heart failure group without diabetes mellitus or abnormal glucose tolerance (n = 84), a diabetes mellitus group without heart failure (n = 86), and a heart failure with diabetes mellitus group (n = 86).TNFR1/2 were significantly higher in patients with heart failure and diabetes mellitus based on mRNA expression to protein expression and serum expression. However, there were no differences in mRNA, protein, and serum levels of TNFR1/2 between the HF group and DM group. Furthermore, there were no differences between the groups in some traditional serum inflammatory markers.This study demonstrated higher expressions of TNFR, NF-kB, and JNK in patients with heart failure and diabetes mellitus. Compared with traditional serum markers, TNFR1 and TNFR2 are associated with heart failure risk in type 2 diabetes mellitus patients. (Int Heart J 2017; 58: 245-249)

show abstract

Section: Discussionmentioning

confidence: 99%

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients

Zhang

et al. 2017

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Studies in affected patients as well as animal models have suggested that the inflammatory and proliferative responses are enhanced in diabetes and may explain the observed increased restenosis rate. [5][6][7][8] Pathological analyses indicate that neointimal formation is characterized by an inflammatory reaction at the site of injury, migration and proliferation of vascular smooth muscle cells (VSMCs), and the synthesis of excess matrix.…”

mentioning

confidence: 99%

Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury

et al. 2003

View full text Add to dashboard Cite

Background-Receptor for advanced-glycation end products (RAGE) and its ligands AGEs and S100/calgranulins have been implicated in a range of disorders. However, the role of RAGE/ligand interaction in neointimal hyperplasia after vascular injury remains unclear. Methods and Results-We examined the expression of RAGE and its ligands after balloon injury of the carotid artery in both Zucker diabetic and nondiabetic rats. Using a soluble portion of the extracellular domain of RAGE, we determined the effects of suppressing RAGE/ligand interaction on vascular smooth muscle cell (VSMC) proliferation and neointimal formation after arterial injury. We demonstrate a significantly increased accumulation of AGE and immunoreactivities of RAGE and S100/calgranulins in response to balloon injury in diabetic compared with nondiabetic rats. Blockade of RAGE/ligand interaction significantly decreased S100-stimulated VSMC proliferation in vitro and bromodeoxyuridine (BrdU)-labeled proliferating VSMC in vivo, and suppressed neointimal formation and increased luminal area in both Zucker diabetic and nondiabetic rats. Conclusions-These

show abstract

“…Diabetic patients have been reported to be at increased risk to develop complications of the procedure during hospitalization and to have higher rates of recurrence and decreased infarct-free survival after hospital discharge. [2][3][4] In long-term follow-up, diabetic patients undergoing percutaneous rather than surgical revascularization had nearly a threefold increase in late mortality. 2 Inhibition of platelet aggregation with abciximab, a monoclonal antibody directed against the glycoprotein (GP) IIb/ IIIa receptor on the platelet surface, has been demonstrated to reduce the risk of ischemic complications in patients with high-risk characteristics undergoing PTCA 5 and to reduce the combined risk of death, myocardial infarction, or revascularization of the target vessel at 6 months.…”

mentioning

confidence: 99%

Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin

Kleiman

Lincoff²,

Dj³

et al. 1998

Circulation

View full text Add to dashboard Cite

Background-After angioplasty, major complications and ischemic events occur more frequently in diabetic than nondiabetic patients. To determine whether treatment with abciximab is effective in reducing these events in diabetics, we analyzed characteristics and outcomes of diabetic patients enrolled in a large multicenter study (EPILOG). Methods and Results-Of 2792 patients enrolled, 638 (23%) were diabetic. Diabetic patients were older, shorter, and heavier; more likely to be female and have three-vessel disease, prior coronary artery bypass graft surgery, a history of hypertension, or a recent myocardial infarction; and less likely to be current smokers than their nondiabetic counterparts. During hospitalization, death, myocardial infarction, or urgent revascularization occurred in 7.1% of diabetics and 7.5% of nondiabetics. By 6 months, the composite of death and myocardial infarction had occurred in 8.8% of diabetic patients and 7.4% of nondiabetics, whereas death, myocardial infarction, or revascularization had occurred in 27.2% and 22.6%, respectively. Abciximab treatment reduced death or myocardial infarction among diabetic and nondiabetic patients (hazard ratios, 0. When standard-and low-dose heparin adjuncts were compared, diabetics receiving abciximab with standard-dose heparin had marginally greater reductions in the composite of death and myocardial infarction and in target vessel revascularization than diabetics assigned to abciximab with low-dose heparin. Conclusions-Abciximab treatment in diabetic patients led to a reduction in the composite of death and myocardial infarction, which was at least as great as that seen in nondiabetic patients. However, target vessel revascularization was reduced in nondiabetic but not diabetic patients. This effect may be associated in part with lower doses of heparin. These differences may be related to differences in the platelet and coagulation systems between diabetics and nondiabetics, the greater extent of coronary artery disease in diabetics, or patient selection and management factors. (Circulation. 1998;97:1912-1920.)

show abstract

Influence of Diabetes Mellitus on Early and Late Outcome After Percutaneous Transluminal Coronary Angioplasty

Cited by 465 publications

References 29 publications

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients

Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury

Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin

Contact Info

Product

Resources

About